2023/2024 update of the national prostate cancer guidelines in Sweden
DOI:
https://doi.org/10.2340/sju.v59.42656Keywords:
Prostate cancer, guidelinesAbstract
N/A
Downloads
References
Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. 2022;56(4):265–273. https://doi.org/10.1080/21681805.2022.2094462 DOI: https://doi.org/10.1080/21681805.2022.2094462
Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease. Scand J Urol. 2022;56(4):278–284. https://doi.org/10.1080/21681805.2022.2093396 DOI: https://doi.org/10.1080/21681805.2022.2093396
Luzzago S, Piccinelli ML, Mistretta FA, et al. Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates. BJU Int. 2022;129(4):524–533. https://doi.org/10.1111/bju.15623 DOI: https://doi.org/10.1111/bju.15623
Kerkmeijer LGW, Groen VH, Pos FJ, et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol. 2021;39(7):787–796. https://doi.org/10.1200/JCO.20.02873 DOI: https://doi.org/10.1200/JCO.20.02873
Murthy V, Maitre P, Kannan S, et al. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol. 2021;39(11):1234–1242. https://doi.org/10.1200/JCO.20.03282 DOI: https://doi.org/10.1200/JCO.20.03282
European Society of Cardiology. ESC guideline on cardio-oncology 2022 [Internet] [cited: 04-03-2024]. Available from: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Cardio-oncology-guidelines
European Medicines Agency. Akeega 2023 [Internet]. [cited 04-03-2024]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/akeega.
Husain H, Pavlick DC, Fendler BJ, et al. Tumor fraction correlates with detection of actionable variants across > 23,000 circulating tumor DNA samples. JCO Precis Oncol. 2022;6:e2200261. https://doi.org/10.1200/PO.22.00261 DOI: https://doi.org/10.1200/PO.22.00261
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Johan Stranne
This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY license, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
